96-week retention in treatment with extended-release subcutaneous buprenorphine depot injections among people with opioid dependence: Extended follow-up after a single-arm trial
Files
(Published version)
Date
2024
Authors
Farrell, M.
Shahbazi, J.
Chambers, M.
Byrne, M.
Gholami, J.
Zahra, E.
Grebely, J.
Lintzeris, N.
Larance, B.
Ali, R.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
International Journal of Drug Policy, 2024; 127:104390-1-104390-11
Statement of Responsibility
Michael Farrell, Jeyran Shahbazi, Mark Chambers, Marianne Byrne, Jaleh Gholami, Emma Zahra, Jason Grebely, Nicholas Lintzeris, Briony Larance, Robert Ali, Suzanne Nielsen, Adrian Dunlop, Gregory J. Dore, Michael McDonough, Mark Montebello, Rob Weiss, Craig Rodgers, Jon Cook, Louisa Degenhardt, on behalf of the CoLAB study team
Conference Name
Abstract
Background: The most recent formulation of buprenorphine treatment is extended-release depot injections (BUPXR) that are administered subcutaneously by health care professionals. This study aimed to observe treatment outcomes of BUP-XR delivered in standard practice during a 96-week follow-up period in a community setting. Methods: This study is an extension of the CoLAB study, a prospective single-arm, multicentre, open label trial (N=100, 7 sites in Australia) among people with opioid dependence who received monthly injections of BUP-XR to evaluate the retention in treatment. Participants were followed for 96 weeks, comprising 48 weeks of the CoLAB study followed by a 48-week extension. Results: Of 100 participants at baseline, 47 were retained on BUP-XR at 96 weeks. The median time retained on monthly depot was 90 weeks. Heroin use (adjusted OR=0.19, P=0.012) in the month prior to baseline was associated with lower odds of retention on BUP-XR. Older age at first opioid use (adjusted OR= 1.08, P=0.009) and longer duration in OAT at baseline (adjusted OR= 1.12, P=0.001) were associated with increased retention. Prevalence of past four-weeks opioid use was estimated at 4% at 96 weeks of treatment (prevalence 0.04, 95%CI: 0.00-0.11) compared to 15% at baseline. Quality of life and medication treatment satisfaction improved over time for those retained in treatment. Conclusion: This is one of the few studies to describe long term (96 week) retention in treatment with BUP-XR in a community setting. It displayed retention rates with 47% of participants completing 96 weeks of treatment with BUP-XR. Patient reported outcomes suggest improvements in client wellbeing. Funding: Indivior
School/Discipline
Dissertation Note
Provenance
Description
Available online 23 March 2024
Access Status
Rights
Crown Copyright © 2024 Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).